primaryid$caseid$caseversion$i_f_code$event_dt$mfr_dt$init_fda_dt$fda_dt$rept_cod$auth_num$mfr_num$mfr_sndr$lit_ref$age$age_cod$age_grp$sex$e_sub$wt$wt_cod$rept_dt$to_mfr$occp_cod$reporter_country$occr_country
122802603$12280260$3$F$20160201$20170411$20160419$20170417$PER$$PHEH2016US008990$NOVARTIS$$35$YR$$F$Y$$$20170417$$CN$COUNTRY NOT SPECIFIED$US
124847382$12484738$2$F$$20160603$20160621$20170622$PER$$US-BAUSCH-BL-2016-007022$BAUSCH AND LOMB$$$$$M$Y$$$20170622$$CN$US$US
125797862$12579786$2$F$$20170405$20160721$20170412$PER$$US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-46604BI$BOEHRINGER INGELHEIM$$$$$M$Y$$$20170412$$CN$US$US
128825143$12882514$3$F$20160810$20170406$20161025$20170412$EXP$$CO-REGENERON PHARMACEUTICALS, INC.-2016-22957$REGENERON$$$$$$Y$$$20170412$$CN$CO$CO
132364913$13236491$3$F$20170119$20170418$20170215$20170421$EXP$$US-ELI_LILLY_AND_COMPANY-US201702003778$ELI LILLY AND CO$$74$YR$$F$Y$48.9$KG$20170421$$MD$US$US
133281592$13328159$2$F$$20170221$20170313$20170516$PER$$US-JNJFOC-20170221847$JANSSEN$$$$E$F$Y$$$20170516$$CN$US$US
133961271$13396127$1$I$20170306$20170330$20170403$20170403$PER$$US-GLAXOSMITHKLINE-US2017045934$GLAXOSMITHKLINE$$20$MON$$F$Y$$$20170403$$CN$US$US
133969531$13396953$1$I$201703$20170328$20170403$20170403$EXP$$JP-ELI_LILLY_AND_COMPANY-JP201703010811$ELI LILLY AND CO$$57$YR$$F$Y$$$20170402$$CN$JP$JP
133972642$13397264$2$F$$20170329$20170403$20170404$EXP$$ES-BIOGEN-2017BI00380428$BIOGEN$$$$A$F$Y$$$20170404$$MD$ES$ES
134018931$13401893$1$I$$20170330$20170404$20170404$EXP$$US-ELI_LILLY_AND_COMPANY-US201703012773$ELI LILLY AND CO$$$$$F$Y$$$20170404$$CN$US$US
134055911$13405591$1$I$$20170330$20170405$20170405$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-027916$BRISTOL MYERS SQUIBB$$$$$M$Y$$$20170405$$OT$US$US
134072401$13407240$1$I$$20170327$20170405$20170405$EXP$$US-TEVA-755546USA$TEVA$TOTONCHY MB, COLEGIO OR, CHRISTENSEN SR. SIROLIMUS-ASSOCIATED RAPID PROGRESSION OF LEG ULCERS IN A RENAL TRANSPLANT RECIPIENT. JAMA-DERMATOL 2017;153(1):105-106.$8$DEC$$F$Y$$$20170406$$MD$US$US
134149581$13414958$1$I$20170404$20170404$20170406$20170406$PER$$US-CELGENEUS-USA-20170401506$CELGENE$$58$YR$$F$Y$$$20170406$$PH$US$US
134150122$13415012$2$F$$20170413$20170406$20170419$EXP$$US-JNJFOC-20170404823$JANSSEN$$$$$F$Y$$$20170419$$CN$US$US
134152351$13415235$1$I$$$20170407$20170407$DIR$US-FDA-368041$$FDA-CTU$$$$$F$N$103.5$KG$20170407$N$OT$US$US
134162631$13416263$1$I$20170221$20170329$20170407$20170407$EXP$LM20170297$FR-NOVOPROD-538992$NOVO NORDISK$$54$YR$A$M$Y$$$20170407$$OT$FR$FR
134184572$13418457$2$F$20140305$20170412$20170408$20170419$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-027006$BRISTOL MYERS SQUIBB$$0$DY$$F$Y$2.89$KG$20170419$$OT$US$US
134214531$13421453$1$I$2005$20170330$20170410$20170410$PER$$US-ASTRAZENECA-2017SE34501$ASTRAZENECA$$$$$F$Y$$$20170410$$CN$US$US
134247521$13424752$1$I$$20170403$20170410$20170410$EXP$$US-TAKEDA-2017TUS007740$TAKEDA$$$$$$Y$$$20170410$$CN$US$US
134250411$13425041$1$I$$20170401$20170410$20170410$EXP$$US-MYLANLABS-2017M1020941$MYLAN$$$$$$Y$$$20170405$$MD$US$US
134260651$13426065$1$I$20170202$20170202$20170411$20170411$PER$$US-JNJFOC-20170203512$JANSSEN$$76$YR$E$M$Y$$$20170411$$CN$US$US
134272081$13427208$1$I$20161123$20170404$20170411$20170411$EXP$$US-GRANULES INDIA LIMITED-1065269$GRANULES INDIA$$59$YR$$F$Y$81.82$KG$20170411$$MD$US$US
134330411$13433041$1$I$$20170227$20170412$20170412$PER$$US-NOVOPROD-534616$NOVO NORDISK$$$$A$F$Y$$$20170412$$OT$US$US
134399471$13439947$1$I$$20170405$20170413$20170413$EXP$$JP-AMGEN-JPNSP2017056649$AMGEN$$$$$$Y$$$20170412$$PH$JP$JP
134469321$13446932$1$I$$20170409$20170417$20170417$PER$$US-PFIZER INC-2017161206$PFIZER$$$$$M$Y$$$20170417$$CN$US$US
134479102$13447910$2$F$2017$20170411$20170417$20170420$EXP$$KR-ABBVIE-17K-090-1884483-00$ABBVIE$$49$YR$$F$Y$70$KG$20170420$$CN$KR$KR
134491341$13449134$1$I$20170324$20170406$20170417$20170417$EXP$$FR-OTSUKA-2017_008748$OTSUKA$$51$YR$$F$Y$$$20170417$$OT$FR$FR
134513951$13451395$1$I$$20170403$20170418$20170418$PER$$CA-APOTEX-2017AP009912$APOTEX$$44$YR$$F$Y$$$20170418$$CN$CA$CA
134518481$13451848$1$I$20170208$20170410$20170418$20170418$EXP$$CN-009507513-1704CHN006819$MERCK$$67$YR$$M$Y$$$20170418$$OT$CN$CN
134538541$13453854$1$I$$20160315$20170418$20170418$PER$$US-ALLERGAN-1651094US$ALLERGAN$$$$$F$Y$$$20170418$$CN$US$US
134553741$13455374$1$I$$20170410$20170418$20170418$PER$$US-JNJFOC-20170411529$JANSSEN$$$$$M$Y$$$20170418$$CN$US$US
134565661$13456566$1$I$$20170411$20170419$20170419$EXP$$PHHY2017BE055527$NOVARTIS$$$$$$Y$$$20170419$$CN$BE$BE
134588131$13458813$1$I$$20170412$20170419$20170419$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-032348$BRISTOL MYERS SQUIBB$$$$$F$Y$$$20170419$$CN$US$US
134596731$13459673$1$I$$20170406$20170419$20170419$EXP$$SE-IPCA LABORATORIES LIMITED-IPC201704-000557$IPCA$$$$A$F$Y$$$20170420$$OT$SE$SE
134597301$13459730$1$I$1999$20151001$20170420$20170420$PER$$US-JNJFOC-20151008461$JANSSEN$$$$A$M$Y$$$20170420$$CN$US$US
134621261$13462126$1$I$20170322$20170322$20170420$20170420$PER$$US-TEVA-753553ACC$TEVA$$23$YR$$F$Y$79$KG$20170420$$MD$US$US
134646231$13464623$1$I$$20101005$20170420$20170420$PER$$US-ROCHE-730938$ROCHE$$$$$M$Y$$$20170421$$LW$US$US
134657041$13465704$1$I$$20170410$20170421$20170421$EXP$$US-BION-006194$BIONPHARMA$HEATH JL, HEATH RD, TAMBOLI C, JOHNSON L, WILSON AS, CHERVINSKIY S, ET AL. MESALAMINE DESENSITIZATION IN A PATIENT WITH TREATMENT REFRACTORY ULCERATIVE COLITIS AND ASPIRIN AND NONSTEROIDAL ANTI-INFLAMMATORY DRUG HYPERSENSITIVITY. ANN ALLERGY ASTHMA IMMUNOL. 2017 APR;118(4):518-520.$33$YR$A$F$Y$$$20170421$$OT$US$US
134661322$13466132$2$F$$20170518$20170421$20170524$PER$$US-PFIZER INC-2017172973$PFIZER$$77$YR$$F$Y$$$20170524$$CN$US$US
134799632$13479963$2$F$$20170502$20170425$20170504$EXP$$FI-PFIZER INC-2017140745$PFIZER$$$$$M$Y$$$20170504$$CN$FI$FI
134837341$13483734$1$I$$20170413$20170426$20170426$EXP$$CA-JAZZ-2017-CA-005114$JAZZ$$$$$$Y$$$20170426$$OT$CA$CA
134936061$13493606$1$I$$20140716$20170427$20170427$PER$$US-ROCHE-1436198$ROCHE$$$$$F$Y$$$20170427$$MD$US$US
135004971$13500497$1$I$20170205$20170426$20170501$20170501$EXP$$DE-ABBVIE-17P-062-1959569-00$ABBVIE$$79$YR$$M$Y$$$20170501$$CN$DE$DE
135009651$13500965$1$I$$20161109$20170501$20170501$PER$$US-ROCHE-1853364$ROCHE$$78$YR$$M$Y$$$20170502$$CN$US$US
135030481$13503048$1$I$20170208$$20170501$20170501$DIR$FDA-CDER-CTU-2017-25946$$FDA-CTU$$59$YR$$F$N$$$20170501$N$PH$US$US
135039561$13503956$1$I$201704$20170421$20170502$20170502$EXP$$US-ABBVIE-17K-163-1957910-00$ABBVIE$$80$YR$$M$Y$59.02$KG$20170502$$MD$US$US
135048351$13504835$1$I$$20170422$20170502$20170502$EXP$$BW-GILEAD-2017-0270525$GILEAD$ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436$$$I$$Y$$$20170502$$MD$BW$BW
135099851$13509985$1$I$$20170403$20170503$20170503$PER$$US-SA-2017SA059903$AVENTIS$$$$A$F$Y$$$20170503$$CN$US$US
135108521$13510852$1$I$20160301$20160415$20170503$20170503$PER$$US-PFIZER INC-3257015$PFIZER$$$$$F$Y$$$20170503$$OT$US$US
135171701$13517170$1$I$20170108$$20170505$20170505$DIR$FDA-CDER-CTU-2017-26923$$FDA-CTU$$91$YR$$F$N$61.8$KG$20170112$N$PH$US$US
135243541$13524354$1$I$$20170427$20170508$20170508$PER$$US-TAKEDA-2017TUS009335$TAKEDA$$$$A$F$Y$$$20170508$$CN$US$US
135247161$13524716$1$I$$20170429$20170508$20170508$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-037922$BRISTOL MYERS SQUIBB$$$$$M$Y$$$20170508$$PH$US$US
135320181$13532018$1$I$$20170426$20170510$20170510$EXP$$GB-CELGENEUS-GBR-20170409273$CELGENE$$54$YR$$M$Y$$$20170510$$OT$GB$GB
135325501$13532550$1$I$20170421$20170428$20170510$20170510$EXP$IT-MINISAL02-407512$IT-TEVA-766398ACC$TEVA$$$$$F$Y$$$20170510$$PH$IT$IT
135326161$13532616$1$I$$20170427$20170510$20170510$EXP$$US-MYLANLABS-2017M1027959$MYLAN$FU P, WEYKER PD, WEBB CA. CASE REPORT OF SERRATUS PLANE CATHETER FOR PAIN MANAGEMENT IN A PATIENT WITH MULTIPLE RIB FRACTURES AND AN INFERIOR SCAPULAR FRACTURE. A-A-CASE-REP 2017;8(6):132-135.$$$$$Y$$$20170510$$MD$US$US
135339341$13533934$1$I$$20170420$20170510$20170510$PER$$US-SA-2017SA074068$AVENTIS$$80$YR$E$M$Y$$$20170510$$CN$US$US
135417411$13541741$1$I$$20170505$20170512$20170512$PER$$PHEH2017US013949$NOVARTIS$$76$YR$$M$Y$$$20170512$$PH$US$US
135431321$13543132$1$I$$$20170512$20170512$DIR$US-FDA-371299$$FDA-CTU$$$$$F$N$83.25$KG$20170512$N$OT$US$US
135494401$13549440$1$I$$20170503$20170516$20170516$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2017US-140620$RANBAXY$SOLOMON R, HOLMER A, SARIN A. MISSING POUNDS; MISSED DIAGNOSIS. J GEN INTERN MED. 2017;40TH ANN MEE$$$$F$Y$$$20170516$$OT$US$US
135498131$13549813$1$I$$20170505$20170516$20170516$EXP$$FR-NORTHSTAR HEALTHCARE HOLDINGS-FR-2017NSR000142$NORTHSTAR$PELISSIER F, DE HARO L, CARDONA F, PICOT C, PUSKARCZYK E, SAPORI JM, ET AL.. SELF-POISONING WITH BACLOFEN IN ALCOHOL-DEPENDENT PATIENTS: NATIONAL REPORTS TO FRENCH POISON CONTROL CENTERS, 2008?2013. CLIN-TOXICOL-(PHILA). 2017;55(4):275-284$49$YR$$M$Y$$$20170516$$OT$FR$FR
135523572$13552357$2$F$2017$20170613$20170517$20170614$EXP$$US-ABBVIE-17K-163-1973710-00$ABBVIE$$35$YR$$M$Y$$$20170614$$CN$US$US
135529151$13552915$1$I$$20170508$20170517$20170517$PER$$US-BIOGEN-2017BI00400330$BIOGEN$$$$$M$Y$$$20170517$$CN$US$US
135571581$13557158$1$I$201703$20170324$20170517$20170517$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-002760$ACADIA PHARMACEUTICALS$$63$YR$$F$Y$$$20170517$$MD$US$US
135629011$13562901$1$I$20170518$$20170518$20170518$DIR$FDA-CDER-CTU-2017-30277$$FDA-CTU$$53$YR$$F$N$$$20170518$N$PH$US$US
135632851$13563285$1$I$20160617$20170118$20170519$20170519$EXP$$JP-BEH-2017077405$CSL BEHRING$$$$I$F$Y$7$KG$20170519$$MD$JP$JP
135802021$13580202$1$I$$20170317$20170525$20170525$PER$$US-PURDUE-USA-2017-0137308$PURDUE$$$$$M$Y$$$20170525$$CN$US$US
135837771$13583777$1$I$20170417$20170428$20170526$20170526$PER$$US-009507513-1705USA003033$MERCK$$23$YR$$F$Y$72.56$KG$20170526$$OT$US$US
135841971$13584197$1$I$$20170515$20170526$20170526$PER$$PHEH2017US014539$NOVARTIS$$$$$F$Y$$$20170526$$MD$US$US
135863091$13586309$1$I$2017$20170519$20170526$20170526$EXP$$US-009507513-1705USA010227$MERCK$$$$$F$Y$$$20170526$$CN$US$US
135891991$13589199$1$I$$20170323$20170529$20170529$PER$$US-APOTEX-2017AP009252$APOTEX$$25$YR$$F$Y$$$20170529$$CN$US$US
135925321$13592532$1$I$201610$20161108$20170530$20170530$PER$$US-PERRIGO-16US021733$PERRIGO$$$$$F$Y$$$20170530$$PH$US$US
135936761$13593676$1$I$$20170516$20170530$20170530$EXP$$IN-ELI_LILLY_AND_COMPANY-IN201705011061$ELI LILLY AND CO$$$$$$Y$$$20170530$$OT$IN$IN
135966301$13596630$1$I$$20161123$20170531$20170531$PER$$US-STRIDES ARCOLAB LIMITED-2016SP019453$STRIDES$COHAN D, MWESIGWA J, NATUREEBA P, ALIBA LUWEDDE F, ADES V, PLENTY A ET AL. WHO OPTION B+: EARLY EXPERIENCE OF ANTIRETROVIRAL THERAPY SEQUENCING AFTER CESSATION OF BREASTFEEDING  AND RISK OF DERMATOLOGIC TOXICITY. J ACQUIR IMMUNE DEFIC SYNDR. 2013;62(3):E101-3$$$$$Y$$$20170531$$OT$US$US
136160081$13616008$1$I$2013$20170601$20170606$20170606$EXP$$BR-ASTRAZENECA-2017SE58900$ASTRAZENECA$$45$YR$$F$Y$$$20170606$$CN$BR$BR
136202581$13620258$1$I$2017$20170601$20170607$20170607$EXP$$MX-UCBSA-2017021780$UCB$$9$YR$$M$Y$23$KG$20170607$$CN$MX$MX
136217941$13621794$1$I$201705$20170601$20170607$20170607$PER$$US-AMGEN-USASP2017084666$AMGEN$$60$YR$A$F$Y$$$20170607$$MD$US$US
136223871$13622387$1$I$$20110505$20170607$20170607$PER$$US-ROCHE-775702$ROCHE$$53$YR$$F$Y$49.4$KG$20170608$$PH$US$US
136287261$13628726$1$I$$20120213$20170531$20170531$PER$$US-ASTELLAS-1042018$ASTELLAS$$$$$M$Y$$$20170526$$CN$US$US
136300761$13630076$1$I$$20130913$20170531$20170531$PER$$US-ASTELLAS-1276247$ASTELLAS$$$$$M$Y$$$20170525$$CN$US$US
136332861$13633286$1$I$20150117$20150119$20170531$20170531$PER$$US-ASTELLAS-1523686$ASTELLAS$$70$YR$$F$Y$$$20170525$$CN$US$US
136342281$13634228$1$I$$20150727$20170531$20170531$PER$$US-ASTELLAS-1614114$ASTELLAS$$$$$M$Y$$$20170526$$CN$US$US
136390571$13639057$1$I$$20170605$20170609$20170609$EXP$$US-BAUSCH-BL-2017-018381$BAUSCH AND LOMB$$$$$F$Y$$$20170609$$CN$US$US
136428391$13642839$1$I$20170222$20170222$20170612$20170612$PER$$US-SEPTODONT-201703895$SEPTODONT$$25$YR$$$Y$$$20170608$$OT$US$US
136504761$13650476$1$I$$20170608$20170614$20170614$PER$$US-AMGEN-USASP2017088468$AMGEN$$63$YR$A$F$Y$$$20170614$$OT$US$US
136648281$13664828$1$I$20170307$20170309$20170619$20170619$PER$$US-APOTEX-2017AP008350$APOTEX$$58$YR$A$F$Y$68$KG$20170619$$CN$US$US
136652022$13665202$2$F$$20170620$20170619$20170629$EXP$$JP-GILEAD-2017-0277620$GILEAD$$$$E$F$Y$$$20170629$$MD$JP$JP
136652271$13665227$1$I$20170616$$20170619$20170619$DIR$US-FDA-374996$$FDA-CTU$$71$YR$$M$N$104.4$KG$20170619$N$CN$US$US
136697271$13669727$1$I$20170320$20170614$20170620$20170620$EXP$RO-NMA-2017-SP16264$RO-AMGEN-ROUSP2017092830$AMGEN$$48$YR$A$F$Y$$$20170620$$MD$RO$RO
136782341$13678234$1$I$$20170616$20170622$20170622$EXP$$US-ABBVIE-17P-163-2011462-00$ABBVIE$$$$$M$Y$$$20170622$$CN$US$US
136794191$13679419$1$I$20170307$20170320$20170622$20170622$PER$$US-LUNDBECK-DKLU2028204$LUNDBECK$$85$YR$$M$Y$$$20170622$$CN$US$US
136811571$13681157$1$I$$20170619$20170623$20170623$PER$$US-AMGEN-USASL2017093844$AMGEN$$62$YR$A$F$Y$$$20170623$$CN$US$US
136842461$13684246$1$I$$20170403$20170623$20170623$PER$$US-ASTELLAS-2017US013423$ASTELLAS$$$$$F$Y$$$20170623$$CN$US$US
136861291$13686129$1$I$$20120508$20170623$20170623$PER$$US-ROCHE-1068413$ROCHE$$$$$F$Y$$$20170623$$CN$US$US
136863481$13686348$1$I$$20120810$20170623$20170623$PER$$US-ROCHE-1100187$ROCHE$$$$$F$Y$$$20170623$$CN$US$US
136869341$13686934$1$I$201701$20170616$20170623$20170623$EXP$$DE-BIOGEN-2017BI00420403$BIOGEN$$50$YR$$F$Y$$$20170623$$CN$DE$DE
136874291$13687429$1$I$$20170612$20170624$20170624$EXP$GB-MHRA-ADR 24016450$GB-TORRENT-00015363$TORRENT$$$$N$$Y$$$20170624$$CN$GB$GB
136987441$13698744$1$I$201706$20170623$20170628$20170628$EXP$$JP-PFIZER INC-2017277430$PFIZER$$$$$$Y$$$20170628$$MD$JP$JP
137054551$13705455$1$I$20160103$20170501$20170630$20170630$EXP$$US-BAYER-2017-084170$BAYER$$84$YR$E$M$Y$$$20170630$$LW$US$US
137055661$13705566$1$I$$20140423$20170630$20170630$PER$$US-IPSEN BIOPHARMACEUTICALS, INC.-2014-2195$IPSEN$$$$$F$Y$$$20170630$$OT$US$US
137086221$13708622$1$I$$20151116$20170630$20170630$PER$$US-IPSEN BIOPHARMACEUTICALS, INC.-2015-08780$IPSEN$$52$YR$$F$Y$$$20170630$$MD$US$US
